ALKBH5 deletion or inhibition enhances the efficacy of anti–PD-1 treatment in colorectal cancer and melanoma [133], suggesting ALKBH5 could represent a promising therapeutic target to enhance immunotherapy outcome in cancer patients. The gene discussed is ALKBH5; the disease is colorectal cancer.